ATE116338T1 - Chemisch modifizierte proteine und deren herstellung. - Google Patents

Chemisch modifizierte proteine und deren herstellung.

Info

Publication number
ATE116338T1
ATE116338T1 AT87103259T AT87103259T ATE116338T1 AT E116338 T1 ATE116338 T1 AT E116338T1 AT 87103259 T AT87103259 T AT 87103259T AT 87103259 T AT87103259 T AT 87103259T AT E116338 T1 ATE116338 T1 AT E116338T1
Authority
AT
Austria
Prior art keywords
chemically modified
modified proteins
group
production
imidoester
Prior art date
Application number
AT87103259T
Other languages
English (en)
Inventor
Hayao Ueno
Masahiko Fujino
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE116338T1 publication Critical patent/ATE116338T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT87103259T 1986-03-10 1987-03-06 Chemisch modifizierte proteine und deren herstellung. ATE116338T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5306186 1986-03-10

Publications (1)

Publication Number Publication Date
ATE116338T1 true ATE116338T1 (de) 1995-01-15

Family

ID=12932327

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87103259T ATE116338T1 (de) 1986-03-10 1987-03-06 Chemisch modifizierte proteine und deren herstellung.

Country Status (8)

Country Link
US (1) US5109120A (de)
EP (1) EP0236987B1 (de)
JP (1) JP2514950B2 (de)
AT (1) ATE116338T1 (de)
CA (1) CA1336967C (de)
DE (1) DE3750906T2 (de)
ES (1) ES2065880T3 (de)
GR (1) GR3015558T3 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681720A (en) * 1986-12-23 1997-10-28 Kyowa Hakko Co., Ltd. DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
ES2084149T3 (es) * 1989-12-01 1996-05-01 Basf Ag Conjugados de hirudinpolialquilenglicol.
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
EP0618927A4 (de) * 1991-12-10 1995-05-24 Tanox Biosystems Inc Cytokine mit einem ungepaarten cystein-rest und konjugaten davon.
WO1993013131A1 (fr) * 1991-12-24 1993-07-08 Sumitomo Seika Chemicals Co., Ltd. Procede pour la production d'un composite proteine/polymere synthetique et composite ainsi produit
US5414135A (en) * 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
TW263437B (de) * 1992-09-24 1995-11-21 Takeda Pharm Industry Co Ltd
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
ATE214940T1 (de) * 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
DE69632062T2 (de) 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
AU766597B2 (en) 1998-05-15 2003-10-16 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
BR9915548A (pt) * 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
EP1535622B1 (de) 1999-04-08 2008-12-31 Schering Corporation Melanoma Therapie
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
CA2390292A1 (en) 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
PT3025726T (pt) 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
CA2491178A1 (en) 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20090214472A1 (en) * 2004-03-01 2009-08-27 Enzon Pharmaceuticals Inc. Interferon-beta polymer conjugates
AU2006259348B2 (en) 2005-06-17 2010-07-22 Novartis Ag Use of sanglifehrin in HCV
EP2007789B1 (de) 2006-04-11 2015-05-20 Novartis AG Spirozyklische HCV/HIV-Hemmer und ihre Verwendung
GB2438834A (en) * 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
JP2011500086A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
EP2459211A1 (de) 2009-07-31 2012-06-06 Medtronic, Inc. Kontinuierliche subkutane verabreichung von interferon an hepatitis-c-patienten
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
CN103179974A (zh) 2010-10-05 2013-06-26 诺华有限公司 丙型肝炎病毒感染的新疗法
JP5909495B2 (ja) 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
CA2818067A1 (en) 2010-11-30 2012-06-07 Novartis Ag New treatments of hepatitis c virus infection
AU2012233644A1 (en) 2011-03-31 2013-09-12 Novartis Ag Alisporivir to treat Hepatitis C virus infection
AU2012237295A1 (en) 2011-04-01 2013-09-19 Novartis Ag Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
CN103648516A (zh) 2011-04-13 2014-03-19 诺华股份有限公司 使用阿拉泊韦治疗丙型肝炎病毒感染
RU2014116988A (ru) 2011-09-27 2015-11-10 Новартис Аг Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
MX387205B (es) 2014-08-19 2025-03-18 Biogen Ma Inc Método de pegilación.
JP6668468B2 (ja) 2015-11-03 2020-03-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146472A (en) * 1913-10-20 1921-10-05 Standard Oil Company Of New Yo Improvements in obtaining products from petroleum by decomposition of component hydrocarbons thereof
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
CH651308A5 (de) * 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4460560A (en) * 1982-06-18 1984-07-17 University Of Southern California Drug delivery by polymeric carriers
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS60176586A (ja) * 1984-02-21 1985-09-10 Sanwa Kagaku Kenkyusho:Kk 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof

Also Published As

Publication number Publication date
JPS6310800A (ja) 1988-01-18
CA1336967C (en) 1995-09-12
EP0236987B1 (de) 1994-12-28
JP2514950B2 (ja) 1996-07-10
EP0236987A3 (en) 1990-05-30
GR3015558T3 (en) 1995-06-30
ES2065880T3 (es) 1995-03-01
DE3750906D1 (de) 1995-02-09
US5109120A (en) 1992-04-28
EP0236987A2 (de) 1987-09-16
DE3750906T2 (de) 1995-06-29

Similar Documents

Publication Publication Date Title
DE3750906D1 (de) Chemisch modifizierte Proteine und deren Herstellung.
FI901530A0 (fi) Menetelmä immunomoduloivien atsaspiraanien valmistamiseksi
KR870000340A (ko) 광학 활성 피리도벤즈옥사진 유도체 및 이의 중간체의 제조방법
EA200000427A1 (ru) Терапевтические применения хинолиновых производных
ATE125550T1 (de) Polypeptid und verfahren zu dessen herstellung.
DE3483869D1 (de) Zusammensetzungen zur bekaempfung von toxaemia.
DK0779291T3 (da) Med heterocyclylcarbonyl substituerede benzofuranyl-urinstoffer
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
EA199800768A1 (ru) Новые производные эритромицина, способ их получения и их применение в качестве медикаментов
ATE36859T1 (de) 4'-demethyl-4-epipodophyllotoxin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ES543153A0 (es) Metodo de preparar derivados de b-carbolin-3-oxadiazolilo
DE3776391D1 (de) Fluessige zubereitungen von 1,2-benzisothiazolin-3-on, ihre herstellung und verwendung.
ATE210136T1 (de) Verfahren zur herstellung von alkylhydrogenchlorsilanen
KR850006187A (ko) 신규 히달토인(Hydantoin) 유도체의 제조방법
DK0392560T3 (da) Diaminoethylenforbindelser
BG104232A (bg) Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцин- 10-оли, метод за тяхното получаване и приложението им като лекарствени средства
DE3876536D1 (de) Oxadiazol-pyrimidinone, ihre herstellung und ihre kosmetische und dermopharmazeutische verwendung.
ES2059595T3 (es) Beta-carbonil-carboxiamidas de 1,3-tiazolidinas.
KR830004210A (ko) 2-아미노-3-벤조일-페닐아세트아미드 및 환상 동족체
DK74189D0 (da) Laegemiddel til behandling af mavesaar
ATE97404T1 (de) Prostazyklin-(pgi2)-analoge.
EP0289804A3 (de) Verfahren zur Herstellung von optisch aktiven Mercapto-Verbindungen
DE3673129D1 (de) Alkylcarbonsaeureamide von pyridinalkylaminen, ihre herstellung und ihre verwendung als arzneimittel.
ATE43342T1 (de) Verfahren zur herstellung von hydrogeno- oder halogenosilanen.
EP0367671A3 (de) Beta-D-phenylthioxyloside, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee